X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
JAB-21822 (glecirasib) is a KRAS G12C inhibitor, small molecule drug candidate which is currently being evaluated for the treatment of KRAS G12C mutated pancreatic cancer.
Lead Product(s): Glecirasib
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
JAB-30300 is an orally bioavailable small molecule, P53 Y220C activator, which is being evaluated for the treatment of patients with solid tumors harboring P53 Y220C mutation.
Lead Product(s): JAB-30300
Therapeutic Area: Oncology Product Name: JAB-30300
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2024
Details:
JAB-3312 is a highly selective SHP2 allosteric inhibitor, in combination with JAB-21822 (glecirasib), a KRAS G12C inhibitor is being evaluated for first-line non-small cell lung cancer patients with KRAS G12C mutations.
Lead Product(s): JAB-3312,Glecirasib
Therapeutic Area: Oncology Product Name: JAB-3312
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2024
Details:
JAB-21822 (glecirasib) is a KRAS G12C inhibitor developed by Jacobio and being developed in KRAS G12C-mutated locally advanced or metastatic pancreatic cancer patients.
Lead Product(s): Glecirasib,JAB-3312
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 07, 2023
Details:
Through the termination, Jacobio will regain the global rights previously granted to AbbVie for SHP2 inhibitor, JAB-3312, including decision-making authority over all development, commercialization, manufacturing, regulatory activities relating to SHP2 inhibitors globally.
Lead Product(s): JAB-3312
Therapeutic Area: Oncology Product Name: JAB-3312
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination July 05, 2023
Details:
Glecirasib is a novel KRAS G12C inhibitor. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors harbouring KRAS G12C mutation, including a pivotal clinical trial int NSCLC in China.
Lead Product(s): Glecirasib,JAB-3312
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 04, 2023
Details:
Under the terms of the agreement, the clinical study will evaluate the clinical effect of JAB-BX102, a CD73 monoclonal antibody in combination with KEYTRUDA (pembrolizumab), provided by merck, for the treatment of advanced solid tumors.
Lead Product(s): JAB-BX102,Pembrolizumab
Therapeutic Area: Oncology Product Name: JAB-BX102
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 22, 2023
Details:
JAB-2485 is a highly selective small molecule Aurora A inhibitor. Preclinical data show that JAB-2485 is highly selective at biochemical and cellular levels. It has potential to benefit patients with small cell lung cancer and triple-negative breast cancer.
Lead Product(s): JAB-2485
Therapeutic Area: Oncology Product Name: JAB-2485
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio. Jacobio has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors.
Lead Product(s): JAB-21822,Cetuximab
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 13, 2022
Details:
JAB-21822 is KRAS G12C inhibitor independently. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.
Lead Product(s): JAB-21822
Therapeutic Area: Oncology Product Name: JAB-21822
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
